Third-generation antipsychotics are dopamine partial agonists rather than dopamine antagonists (decreasing dopamine). They still decrease dopamine like first- and second-generation medications but allow for some dopamine to remain.
This, paired with the continued serotonin targets, is an intentional design to further lessen the worsening of negative and cognitive symptoms. In fact, it may partially improve these symptoms.
Examples of third-generation antipsychotics include:
aripiprazole (Abilify)
brexpiprazole (Rexulti)
cariprazine (Vraylar)
lumateperone (Caplyta)
I didn’t know Abilify etc were considered “third” generation.